VEGFA and wet macular degeneration: Intravitreal anti-vascular endothelial growth factor (VEGF) medications bevacizumab and ranibizumab are recognized for improving visual outcomes and decreasing macular fluid in patients with neovascular age-related macular degeneration (AMD) [1, 2].